Wordt geladen...
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
With an explosion of available treatments for metastatic renal cell carcinoma (mRCC) in recent years, it is important to recognize that approved targeted therapies fall broadly into only two mechanistic categories. The first category, vascular endothelial growth factor (VEGF)-directed therapies, inc...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2011
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3253822/ https://ncbi.nlm.nih.gov/pubmed/21484496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-011-0172-y |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|